Glenmark's Monroe facility concludes USFDA inspection
Glenmark Pharmaceuticals has received Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the United States Food & Drug Administration (U.S. FDA) for its formulations manufacturing facility situated in Monroe, North Carolina, USA. This is following an inspection conducted by the Agency from 09 June to 17 June 2025. The commercial manufacturing at the Monroe site will now restart.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Nov 27 2025 | 10:43 AM IST